BREAKING NEWS 'Do not eat' warning issued as popular ready-meal is urgently pulled from shelves due to risk of deadly reaction
Health chiefs last night issued an urgent recall of La Famiglia Rana Slow-Cooked Braised Beef Lasagne, citing 'a packing error' as the cause of the issue.
The Food Standards Agency warned that 'some packs may contain Prawn & Lobster Lasagne, that contains crustaceans, (prawns and lobster), which are not mentioned on the label'.
This means the product is a possible health risk for anyone with an allergy to crustaceans.
The affected product is La Famiglia Rana Slow-Cooked Braised Beef Lasagne, in the pack size of 700g.
Shoppers should look for batch code L0B510816, with a use by 17 June 2025.
The alert claims Giovanni Rana Ltd 'is recalling the above product from customers' and the company added: 'If you have bought the above product and have an allergy to crustaceans, do not eat it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
27 minutes ago
- Daily Mail
Experts discover Covid triggers condition linked to dementia - and one group is most at risk
A new study has revealed that even mild Covid can age your blood vessels by up to five years, increasing your long-term risk of heart disease, strokes and dementia. Known medically as vascular aging, it sees the blood vessels which carry vital oxygen to organs in the body stiffen, and is normal as we get older. But according to the new study, which included 2,390 people from 16 different countries, it is accelerated by the virus. It was particularly acute in women, wrote the French researchers in the findings, published in the European Heart Journal. Previous studies have shown vascular aging to be linked to an increased risk of developing the memory-robbing illness dementia. The latest study also found people who had been vaccinated against Covid generally had arteries that were less stiff than those who were unvaccinated. And for these people, over the long term, the vascular aging seemed to stabilise or improve slightly. On their findings, lead author, Professor Rosa Maria Bruno from Université Paris Cité, said: 'We know that Covid can directly affect blood vessels. 'We believe that this may be a result of vascular aging, meaning your blood vessels are older than your chronological age and you are more susceptible to heart disease. 'If that is happening, we need to identify who is at risk at an early stage to prevent heart attacks and strokes.' They assed vascular age with a device that measures the speed at which a wave of blood pressure travels called a carotid-femoral pulse wave velocity (PWV). This is how fast the blood is able to flow from the neck to the legs, and the higher the measurement, the stiffer the blood vessels and higher the vascular age. The researchers took measurements six months after a Covid infection and again after 12 months. They found the average increase in PWV in women with it mildly was 0.55 meters per second, 0.60 in women hospitalized, and 1.09 for women treated in intensive care. In a 60-year-old woman, an increase in 0.5 meters per second was considered 'clinically relevant' as it is equal to five years of aging, and raises risk of heart disease. Professor Bruno said there are 'several possible explanations' for why the virus accelerates this vascular aging. But she added, it is likely due to the way in which the virus is able to infect cells due to something called angiotensin-converting enzyme 2 receptors. The virus's interaction with these receptors in the lining of blood vessels, she said 'may result in vascular dysfunction and accelerated vascular aging'. However, it may also be a result of 'our body's inflammation and immune responses, which defend against infections', she added On the increased aging in women, she said: 'One of the main differences between women and men could be differences in the function of the immune system. 'Women mount a more rapid and robust immune response, which can protect them from an infection.' Fortunately, she added, vascular aging can be addressed with lifestyle changes, as well as drugs to lower blood pressure and cholesterol. The team will continue to follow the participants over the following years to determine if accelerated vascular aging leads to increased risk of heart attacks and strokes. In a recent editorial on the findings, Dr Behnood Bikdeli from Harvard Medical School said: 'Although the acute threat of the Covid-19 pandemic has waned, a new challenge emerged in its aftermath.' This is, he explained, post-acute Covid-19 syndrome—defined by the World Health Organization (WHO) as symptoms that last at least two months post-infection. He continued: 'The question is whether we can find modifiable targets to prevent this in future surges of infection.' He also added that the findings could pave the way for finding ways to help people with symptoms of Covid-induced vascular aging.
Daily Mail
27 minutes ago
- Daily Mail
Psychotherapist reveals key warning sign that your everyday stress is about to tip you over the edge, triggering a mental breakdown
It's hard not to feel completely overwhelmed by life at times, but a psychotherapist has shared the one of the critical warning signs that you've gone from worrying about things at a normal level to developing full blown anxiety. Anxiety is a natural reaction to stress and uncertainty, and can be triggered from anything between making presentation at work to proposing to the love of your life. But while the feeling of 'nerves' usually subside after the completion of the stressful event, sometimes the anxiety lingers, and for some people, it becomes louder and louder until performing basic tasks becomes an exhausting—and sometimes scary—uphill struggle. Therapist Clare Patterson, who is registered with the British Association for Counselling and Psychotherapy (BACP), describes anxiety as when 'the body's alarm system [is] stuck in the 'on' position—without a clear, present danger.' But how do you know that your normal worrying levels have got out of control? Ms Patterson shared eight warning signs that you might be heading towards developing a serious mental illness. Speaking to The Sun, she said one of the biggest red flags is catastrophising, when you focus on what could go wrong, or you're obsessing about future events which are totally out of your control. 'You might be trying to focus at work but your mind is pinging from, "I forgot to book the dentist" to "Do I have cancer?" to "I should drink more water", all in 30 seconds.' She added: 'You might lie awake at 2am thinking, "What if I lose my job? What if I can't pay the mortgage? What if I end up homeless?", even when nothing has changed at work. 'You may also catastrophise, always assuming the worst-case scenario. For example, your partner doesn't reply to a message for a few hours and your brain jumps to, "They're in a crash" or "They're leaving me". 'You may also be in a meeting and notice every change in someone's tone, face or body language, and be convinced it means something bad about you.' Catastrophising can leave someone feeling permanently overwhelmed, and cause them to withdraw from their loved ones and routines, which are both other symptoms the mental health expert pinpointed. 'For people with an anxiety disorder, the excessive stress hormones can feel is not "all in their heads". It is a very real, physiological response. 'A low-level fear with no clear object, like waking up with a pit in your stomach for no reason, just a vague feeling something is going to go wrong today, is also common. 'Some people also find their anxiety is internalised and they keep thinking, "What is wrong with me?" 'You might cancel plans because you're feeling overwhelmed, then spend hours criticising yourself for being "flaky" or "too sensitive".' Ms Patterson added that feelings of indecisiveness and perfectionism can also be warning signs that your worrying is getting unhealthy. She said: 'This often leads a person to second guess even small decisions, like what to wear or what to say in a text. 'Anxiety can lead to perfectionism and procrastination, putting off work because it's never quite good enough.' Other signs manifest physically; tension in the body, and restlessness. Ms Patterson said that people who lack 'coping mechanisms'— are at risk of their anxiety becoming out of control. She defines a coping mechanism as steps someone can take to 'feel safe', which might include positive self-talk, seeking out a familiar face at a party or event, or focusing on their breathing. But people who are very anxious can find themselves falling into a panic attack. She said: 'The rational part of their brain may be overwhelmed by the anxiety and so they exist in a fight/flight/freeze state where there is a lack of trust in themselves to cope and manage. 'This can trigger even more anxiety, sending them into a spiral, and even lead to physical symptoms including panic attacks, headaches and dizziness.' It's estimated that 8 million Britons are living with anxiety, and NHS trusts across the UK are struggling to provide suitable support. In February, after analysing NHS stats, Rethink Mental Illness found that the longest waits for mental health care are over two years (658 days), more than twice as long as the ones for people needing elective physical health treatment (299 days). The delays in treatment have seen people turning to online therapy providers, mindfulness self-help books, and in the case of Gen Z, crafting. Findings from The Power of Making report, commissioned by Hobbycraft and in partnership with mental health charity Mind, surveyed nearly 6,000 people nationwide and found that younger people are turning to crochet and pottery kits to try and calm their anxious minds.
Reuters
28 minutes ago
- Reuters
The race to launch first weight-loss pill
August 19 - Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables. Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market: Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up. Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial. The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations. Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter. The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies. AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead. Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year. The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism. In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo. Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.
